B. Childs

发表

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.

Robert Gray, Sunil Badve, Edith A Perez, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140).

J. Nemunaitis, S. Novello, D. Fennell, 2016 .

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.

K. Nackaerts, L. Kasten, S. Novello, 2022, The Lancet. Oncology.

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

G. Salles, G. Lenz, K. Ardeshna, 2020, Leukemia.

Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.

J. Hainsworth, A. Grothey, L. Hart, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study.

J. Hainsworth, L. Hart, B. Childs, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OA 02.01 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma

K. Nackaerts, S. Novello, G. Ceresoli, 2017 .

Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.

A. Santoro, A. Nagler, G. Follows, 2021, Blood advances.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

G. Lenz, A. Santoro, A. Nagler, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.

A. Zelenetz, J. Glassman, J. Bertino, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma

B. Childs, Jun Zhu, J. Garcia-Vargas, 2022, Cancer Chemotherapy and Pharmacology.

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.

P. Zinzani, I. Bondarenko, Tongyu Lin, 2021, The Lancet. Oncology.

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma

A. Santoro, P. Zinzani, S. Leppä, 2021, Clinical lymphoma, myeloma & leukemia.

Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.

B. Childs, L. Schwartzberg, S. Badarinath, 2014, Clinical breast cancer.

Phase II Multicenter Study of Docetaxel and Bevacizumab ± Trastuzumab as First-Line Treatment of Patients With Metastatic Breast Cancer

B. Childs, L. Schwartzberg, S. Badarinath, 2013 .

Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer

L. Hart, H. Burris, D. Yardley, 2013, Breast Cancer Research and Treatment.

Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions.

S. Mackinnon, G. Heller, B. Childs, 1999, Blood.

Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course.

B. Childs, G. McDonald, J. Fingeroth, 1994, Blood.

Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.

R. Wenham, T. Herzog, B. Childs, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.

P. Zinzani, M. Dreyling, B. Childs, 2013, Clinical advances in hematology & oncology : H&O.

Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity.

A. Grothey, B. Childs, H. Hochster, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT199: Larotrectinib in TRK fusion cancer patients: Outcomes by prior therapy and performance status

A. Drilon, J. Berlin, D. Hong, 2020 .

Quality of life of adults and children with TRK fusion cancer treated with larotrectinib compared to the general population.

A. Drilon, J. Berlin, S. Leyvraz, 2020 .

Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.

A. Drilon, B. Geoerger, J. Grilley-Olson, 2019, Journal of Clinical Oncology.

Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.

Edith A Perez, E. Perez, S. Martino, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High Dose Chemotherapy with Autologous Stem Cell Rescue in Adults with Malignant Primary Brain Tumors

M. Rosenblum, J. Finlay, L. Abrey, 1999, Journal of Neuro-Oncology.

190 T-cell depleted (SBA-E-) bone marrow transplantation for myelodysplastic syndromes

B. Childs, James W. Young, T. Small, 1997 .

Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

A. Drilon, J. Berlin, B. Geoerger, 2019, Annals of Oncology.

GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer.

R. Gray, S. Martino, G. Sledge, 2009 .

Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

G. Lenz, A. Santoro, A. Nagler, 2018, Blood.

Abstract CT215: CHRONOS-1: Open-label, uncontrolled phase II trial of intravenous phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib in patients with relapsed, indolent Non-Hodgkin's lymphomas (iNHL)

M. Dreyling, B. Childs, L. Cupit, 2015 .

High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.

L. Deangelis, J. Cairncross, S. Rosenfeld, 2006, Neuro-oncology.

High-dose Chemotherapy with Stem Cell Rescue as Initial Therapy for Anaplastic Oligodendroglioma

L. Deangelis, J. Cairncross, S. Rosenfeld, 2003, Journal of Neuro-Oncology.

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer

A. Drilon, J. Berlin, D. Hyman, 2020, Zeitschrift für Gastroenterologie.

Hyperfractionated total lymphoid irradiation and cyclophosphamide for preparation of previously transfused patients undergoing HLA-identical marrow transplantation for severe aplastic anemia.

Z. Fuks, B. Shank, B. Childs, 1994, International journal of radiation oncology, biology, physics.

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

J. Hainsworth, L. Hart, L. Fehrenbacher, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RIP kinase is involved in arsenic-induced apoptosis in multiple myeloma cells

J. Michaeli, R. Pearse, R. Feinman, 2004, Apoptosis.

Comparison of Immune Reconstitution After Unrelated and Related T-Cell – Depleted Bone Marrow Transplantation : Effect of Patient Age and Donor Leukocyte Infusions

S. Mackinnon, G. Heller, B. Childs, 1998 .

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.

M. Ladanyi, A. Drilon, J. Berlin, 2020, The Lancet. Oncology.

A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.

B. Monk, R. Wenham, M. Einstein, 2014, Gynecologic oncology.

MA09.07 Activity of Larotrectinib in TRK Fusion Lung Cancer

A. Drilon, D. Hyman, S. Kummar, 2019, Journal of Thoracic Oncology.

Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer

M. Pegram, S. Pal, B. Childs, 2009, Breast Cancer Research and Treatment.

Triple negative breast cancer: unmet medical needs

M. Pegram, S. Pal, B. Childs, 2011, Breast Cancer Research and Treatment.

T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease.

S. Mackinnon, G. Heller, B. Childs, 1998, Blood.

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

J. Nemunaitis, J. Bendell, B. Childs, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria

S. Jhanwar, H. Thaler, K. Nafa, 2001, British journal of haematology.

transmission rate and clinical course Marrow transplantation from hepatitis C virus seropositive donors

B. Childs, G. McDonald, D. Snyder, 2011 .

Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

G. Lenz, A. Santoro, A. Nagler, 2019, American journal of hematology.

Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer

L. Bosserman, D. Slamon, B. Childs, 2014, SpringerPlus.

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma

V. Mazzaferro, M. Teufel, J. Llovet, 2018, Clinical Cancer Research.

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

P. Zinzani, D. Cunningham, G. Verhoef, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM a PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

G. Lenz, K. Ardeshna, B. Childs, 2017 .

COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA (CHRONOS‐1)

G. Lenz, A. Santoro, A. Nagler, 2017 .

Abstract CT212: CHRONOS-2: A randomized, double-blind phase III study of phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL)

B. Childs, G. Nowakowski, F. Hiemeyer, 2015 .

Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma

D. Cunningham, M. Dreyling, B. Childs, 2014 .

Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

R. Gray, E. Perez, S. Martino, 2011, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

Silvana, R. Gray, E. Perez, 2011 .

Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB 7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

R. Gray, E. Perez, S. Martino, 2011 .

HER2 concordance between central laboratory immunohistochemistry and quantitative reverse transcription polymerase chain reaction in Intergroup Trial E2197

R. Gray, G. Sledge, S. Shak, 2008 .

Concordance of local and central laboratory hormone and HER2 receptor status in ECOG 2197

R. Gray, S. Shak, S. Badve, 2007 .

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

J. Hainsworth, J. Mackey, D. Walde, 2013, The Lancet. Oncology.

Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer

R. Gray, E. Perez, S. Martino, 2009, Clinical Cancer Research.

Reply to J.M. Guinebretiere and L. Arnould et al

E. Perez, S. Martino, G. Sledge, 2009 .

A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)

L. Raez, B. Childs, J. Wade, 2013, Cancer Chemotherapy and Pharmacology.

Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer

M. Teufel, B. Melichar, J. Jassem, 2017, Targeted Oncology.

Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer

J. Hainsworth, J. Mackey, T. Pintér, 2010 .

Larotrectinib efficacy and safety in adult TRK fusion cancer patients.

A. Drilon, J. Berlin, R. Doebele, 2019, Journal of Clinical Oncology.

Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

A. Drilon, A. Italiano, G. Vassal, 2020, Cancers.

Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.

A. Drilon, J. Berlin, B. Geoerger, 2021, Current problems in cancer.

PI3K inhibitors in haematological malignancies.

P. Zinzani, B. Childs, M. Matasar, 2022, The Lancet. Oncology.

Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

B. Childs, P. Rajagopalan, C. Xia, 2018 .

Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study

B. Monk, L. Kasten, A. Schlicker, 2022, International Journal of Gynecological Cancer.

Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors

J. Reid, B. Childs, P. N. Morcos, 2023, Clinical and translational science.

Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study

J. Kuroda, K. Tobinai, D. Maruyama, 2022, International Journal of Hematology.

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.

M. Ladanyi, S. Mackinnon, B. Childs, 1994, The New England journal of medicine.

Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.

S. Mackinnon, B. Childs, T. Small, 1995, Blood.

Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

G. Salles, A. Santoro, G. Follows, 2017 .

Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

G. Salles, G. Lenz, K. Ardeshna, 2017 .

Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.

N. Shukla, B. Geoerger, S. Bielack, 2019, Journal of Clinical Oncology.

Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation.

B. Childs, J. Laver, F. Boulad, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.

M. Teufel, V. Heinemann, B. Melichar, 2014 .

Risk of extramedullary relapse following allogeneic bone marrow transplantation for acute myelogenous leukemia with leukemia cutis

G. Heller, B. Childs, T. Small, 1997, Bone Marrow Transplantation.

Activity of larotrectinib in TRK fusion lung cancer.

A. Drilon, S. Kummar, L. Rosen, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab

B. Childs, P. N. Morcos, F. Hiemeyer, 2023, CPT: pharmacometrics & systems pharmacology.

Antileukemia activity of a natural killer cell line against human leukemias.

P. Steinherz, B. Childs, R. O'reilly, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

EFFICACY AND SAFETY IN HIGH‐RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB

G. Lenz, A. Santoro, A. Nagler, 2019, Hematological Oncology.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

G. Lenz, A. Santoro, A. Nagler, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones

L Luzzatto, L. Luzzatto, B. Childs, 2002, Leukemia.

Model‐Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen

B. Childs, F. Hiemeyer, D. Garmann, 2024, Clinical pharmacology and therapeutics.